Stock Track | Twist Bioscience Plunges 6.22% in Pre-market as Fiscal Q3 Loss Wider Than Expected

Stock Track08-03

Twist Bioscience Corp (TWST) shares tumbled 6.22% in pre-market trading on Monday after the company reported a wider-than-expected fiscal third-quarter loss, overshadowing a revenue beat and raised full-year guidance.

The synthetic biology company posted a net loss of $0.56 per diluted share, swinging from a profit of $0.33 per share in the same quarter last year. Analysts surveyed by FactSet had anticipated a loss of $0.51 per share. Revenue for the quarter ended June 30 rose 23% year-over-year to $118.4 million, topping the consensus estimate of $114.5 million. Looking ahead, Twist Bioscience raised its fiscal 2026 revenue outlook to a range of $456 million to $457 million, up from its prior guidance of $442 million to $447 million, and forecast fourth-quarter revenue of approximately $123 million to $124 million — both above analyst expectations.

Despite the upbeat guidance and revenue performance, the bottom-line miss and the swing to a loss weighed heavily on investor sentiment, driving the pre-market decline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1103954853?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-03 19:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103954853","market":"sg","top_or_hot":-1,"title":"Stock Track | Twist Bioscience Plunges 6.22% in Pre-market as Fiscal Q3 Loss Wider Than Expected","media":"Stock Track","content":"<p>Twist Bioscience Corp (TWST) shares tumbled 6.22% in pre-market trading on Monday after the company reported a wider-than-expected fiscal third-quarter loss, overshadowing a revenue beat and raised full-year guidance.</p><p>The synthetic biology company posted a net loss of $0.56 per diluted share, swinging from a profit of $0.33 per share in the same quarter last year. Analysts surveyed by FactSet had anticipated a loss of $0.51 per share. Revenue for the quarter ended June 30 rose 23% year-over-year to $118.4 million, topping the consensus estimate of $114.5 million. Looking ahead, Twist Bioscience raised its fiscal 2026 revenue outlook to a range of $456 million to $457 million, up from its prior guidance of $442 million to $447 million, and forecast fourth-quarter revenue of approximately $123 million to $124 million — both above analyst expectations.</p><p>Despite the upbeat guidance and revenue performance, the bottom-line miss and the swing to a loss weighed heavily on investor sentiment, driving the pre-market decline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Twist Bioscience Plunges 6.22% in Pre-market as Fiscal Q3 Loss Wider Than Expected</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Twist Bioscience Plunges 6.22% in Pre-market as Fiscal Q3 Loss Wider Than Expected\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-03 19:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Twist Bioscience Corp (TWST) shares tumbled 6.22% in pre-market trading on Monday after the company reported a wider-than-expected fiscal third-quarter loss, overshadowing a revenue beat and raised full-year guidance.</p><p>The synthetic biology company posted a net loss of $0.56 per diluted share, swinging from a profit of $0.33 per share in the same quarter last year. Analysts surveyed by FactSet had anticipated a loss of $0.51 per share. Revenue for the quarter ended June 30 rose 23% year-over-year to $118.4 million, topping the consensus estimate of $114.5 million. Looking ahead, Twist Bioscience raised its fiscal 2026 revenue outlook to a range of $456 million to $457 million, up from its prior guidance of $442 million to $447 million, and forecast fourth-quarter revenue of approximately $123 million to $124 million — both above analyst expectations.</p><p>Despite the upbeat guidance and revenue performance, the bottom-line miss and the swing to a loss weighed heavily on investor sentiment, driving the pre-market decline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TWST","symbol_name":"Twist Bioscience Corp","start_time":0,"source_url":"","article_id":"1103954853","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103954853","pubTimestamp":1785756986,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Twist Bioscience Corp (TWST) shares tumbled 6.22% in pre-market trading on Monday after the company reported a wider-than-expected fiscal third-quarter loss, overshadowing a revenue beat and raised...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TWST":"Twist Bioscience Corp"},"translate_title":"股票跟踪 | Twist Bioscience 第三财季亏损超出预期，盘前暴跌 6.22%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TWST":1},"content_text":"Twist Bioscience Corp (TWST) shares tumbled 6.22% in pre-market trading on Monday after the company reported a wider-than-expected fiscal third-quarter loss, overshadowing a revenue beat and raised full-year guidance.The synthetic biology company posted a net loss of $0.56 per diluted share, swinging from a profit of $0.33 per share in the same quarter last year. Analysts surveyed by FactSet had anticipated a loss of $0.51 per share. Revenue for the quarter ended June 30 rose 23% year-over-year to $118.4 million, topping the consensus estimate of $114.5 million. Looking ahead, Twist Bioscience raised its fiscal 2026 revenue outlook to a range of $456 million to $457 million, up from its prior guidance of $442 million to $447 million, and forecast fourth-quarter revenue of approximately $123 million to $124 million — both above analyst expectations.Despite the upbeat guidance and revenue performance, the bottom-line miss and the swing to a loss weighed heavily on investor sentiment, driving the pre-market decline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1103954853","isCrawlerRequest":true}